---
title: "Australian Clinical Labs Updates Market on Ongoing On-Market Share Buy-Back"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282118470.md"
description: "Australian Clinical Labs Ltd (ASX: ACL) has announced an ongoing on-market share buy-back as part of its capital management strategy. The company has repurchased a total of 7,505,380 shares, with an additional 128,173 shares bought back recently. This initiative aims to optimize the balance sheet and enhance shareholder value by reducing share count, potentially improving earnings per share. The latest analyst rating for ACL stock is a Hold with a price target of A$2.00. The company operates in the healthcare diagnostics sector, focusing on pathology and laboratory testing services across Australia."
datetime: "2026-04-09T01:42:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282118470.md)
  - [en](https://longbridge.com/en/news/282118470.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282118470.md)
generator: "portal-rs"
---

# Australian Clinical Labs Updates Market on Ongoing On-Market Share Buy-Back

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.

Australian Clinical Labs has disclosed an on-market share buy-back of its ordinary fully paid securities, identified by the ASX code ACL, as part of an ongoing capital management initiative. The company reported that a total of 7,505,380 shares had been repurchased before the previous trading day, with an additional 128,173 shares bought back on the most recent day, indicating continued execution of its previously announced buy-back program and a likely focus on balance sheet optimization and shareholder value.

The latest filing is an update to the buy-back initially notified in October 2025, with this announcement dated 9 April 2026 and marked as a daily buy-back notification. By steadily reducing its share count through on-market purchases, Australian Clinical Labs may enhance earnings per share and signal confidence in its valuation, which can be supportive for existing shareholders and may influence the stock’s liquidity and trading dynamics.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

**More about Australian Clinical Labs Ltd**

Australian Clinical Labs Ltd operates in the healthcare diagnostics sector, providing pathology and laboratory testing services across Australia. The company focuses on medical testing for doctors, hospitals, and other healthcare providers, positioning itself as a key player in clinical laboratory services on the ASX under the code ACL.

**Average Trading Volume:** 803,451

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$387.7M

### Related Stocks

- [ACL.AU](https://longbridge.com/en/quote/ACL.AU.md)

## Related News & Research

- [ACL: Strong FY26 margin and cash flow, with stable outlook and continued shareholder returns](https://longbridge.com/en/news/296033240.md)
- [Australian Clinical Labs Sets Date and Nomination Deadline for 2026 AGM](https://longbridge.com/en/news/295354918.md)
- [Northern Star Resources GAAP EPS of A$0.11, revenue of A$7.62B](https://longbridge.com/en/news/296522899.md)
- [Can Deterra Royalties (ASX:DRR) Justify Its Valuation On Strong FY2026 Results?](https://longbridge.com/en/news/296349201.md)
- [Aurizon Holdings (ASX:AZJ), Why Is Its Latest Update Drawing Attention?](https://longbridge.com/en/news/296393640.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**